TumourGraft
TumourGraft: Cancer diagnostic using PDX models. Global launch in UK, Israel, Singapore, USA. Shifted to pharmaceutical partnerships from patient services, expanding revenue and ensuring technology sustainability.
PredictRx
PredictRx: In-vitro diagnostic for cancer drug sensitivity. Led global commercialisation for clinical use and research. Established Indian reference lab, sales channels in UK, South Africa, Scandinavia. Facilitated successful exit strategy for Imagen Therapeutics.
Caris molecular intelligence
Caris Molecular Intelligence: Molecular profiling for cancer therapy biomarkers. Introduced first UK technology, formed global Expert Panel. Earned NICE endorsement, PMI reimbursement in private sector. Top international distributor for Caris, achieving substantial annual growth.
Taylor spatial frame
Taylor Spacial Frame: External fixator for complex fractures. Developed education program, industry standard for fixator training. Surgeon training increased from 5-10 to >50, leading TSF to sustained high growth and success.
Exogen
Exogen: Ultrasound device for non-union bone fracture healing. Introduced new reimbursement segment, gaining approval for >9-month non-unions. Achieved positive reimbursement with private funders, boosting sales significantly in non-surgical portfolio.
SPATZ gastric balloon
The SPATZ Gastric Balloon: Innovative weight management tool, minimally invasive. Secured UK private sector approval and reimbursement. Executed a robust sales strategy, fostering collaborations with major providers. Led national surgeon training and local customer service, driving NHS adoption.
Bonefos
Generic drug strategic relaunch: Built team, executed one-year campaign for Bayer UK. Achieved fivefold profit increase with innovative sales and marketing, surpassing expectations for significant company success.
Herceptin subcutaneous
Novel Herceptin formulation for breast cancer. Led cross-functional team in national sales, marketing, medical, and reimbursement strategy. Formed a national KOL advisory board and orchestrated successful launch meetings. Achieved Roche’s highest sales uptake for a product launch.
AvandaMet
AvandaMet: Type 2 diabetes combo drug for primary care. Led strategy integrating marketing, PCT reimbursement, and secondary care endorsement. Launched GP and pharmacist training, boosting adoption. Achieved 75% market penetration in 12 months, marking a top GSK primary care launch.
Vismodegib (Erivedge)
